La Trobe

Impact of letrozole versus clomiphene citrate on endometrial receptivity in Iraqi women with polycystic ovarian syndrome

journal contribution
posted on 2025-10-22, 23:01 authored by Manal Al-Obaidi, Zainab Ali, Wasan Al-Saadi, Estabraq Al-Wasiti, Hayder Al-AubaidyHayder Al-Aubaidy
What is known and objectives: Letrozole is widely known for its use as an ovulation inductor. This study aims to investigate the effects of letrozole and clomiphene citrate in females with polycystic ovarian syndrome. Methods: This is a randomized non-blinded controlled trial study that included 80 infertile females with polycystic ovarian syndrome receiving a standard dose of either clomiphene citrate or letrozole on day 2 of the cycle. An ultrasound was done to examine growth of the follicle, endometrial thickness on days 12-13, and a Doppler study to measure resistance index (RI), pulsatility index and ratio of systolic/diastolic velocity. Results and Discussion: The mean levels of dominant follicle and oestradiol were significantly higher in the clomiphene citrate group than in the letrozole group. The letrozole group had a significantly greater endometrial thickness than the clomiphene citrate group. The resistance index and pulsatility index were lower in the letrozole group and in pregnant women than in the clomiphene citrate group and the non-pregnant group. What is new and Conclusion: The use of letrozole for ovulation induction in polycystic ovarian syndrome patients has a better effect on endometrial receptivity markers when compared to clomiphene citrate.

History

Publication Date

2019-08-01

Journal

Journal of Clinical Pharmacy and Therapeutics

Volume

44

Issue

4

Pagination

5p. (p. 618-622)

Publisher

Wiley

ISSN

0269-4727

Rights Statement

© 2019 John Wiley & Sons Ltd. This is the peer reviewed version of the following article: Al-Obaidi M; Ali Z; Al-Saadi W; Al-Wasiti E & Al-Aubaidy H (2019). Impact of letrozole versus clomiphene citrate on endometrial receptivity in Iraqi women with polycystic ovarian syndrome. Journal of Clinical Pharmacy and Therapeutics, 44(4), 618-622, which has been published in final form at http://doi.org/10.1111/jcpt.12831. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. This article may not be enhanced, enriched or otherwise transformed into a derivative work, without express permission from Wiley or by statutory rights under applicable legislation. Copyright notices must not be removed, obscured or modified. The article must be linked to Wiley’s version of record on Wiley Online Library and any embedding, framing or otherwise making available the article or pages thereof by third parties from platforms, services and websites other than Wiley Online Library must be prohibited.